International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

被引：238

作者：

Cavo, Michele ^{[1
]}

Rajkumar, S. Vincent ^{[2
]}

Palumbo, Antonio ^{[3
]}

Moreau, Philippe ^{[4
]}

Orlowski, Robert ^{[5
]}

Blade, Joan ^{[6
]}

Sezer, Orhan ^{[7
]}

Ludwig, Heinz ^{[8
]}

Dimopoulos, Meletios A. ^{[9
]}

Attal, Michel ^{[10
]}

Sonneveld, Pieter ^{[11
]}

Boccadoro, Mario ^{[12
]}

Anderson, Kenneth C. ^{[13
]}

Richardson, Paul G. ^{[13
]}

Bensinger, William ^{[14
]}

Johnsen, Hans E. ^{[15
]}

Kroeger, Nicolaus ^{[16
]}

Gahrton, Gosta ^{[17
]}

Bergsagel, P. Leif ^{[18
]}

Vesole, David H. ^{[19
]}

Einsele, Hermann ^{[20
]}

Jagannath, Sundar ^{[21
]}

Niesvizky, Ruben ^{[22
]}

Durie, Brian G. M. ^{[23
]}

San Miguel, Jesus ^{[24
]}

Lonial, Sagar ^{[25
]}

机构：

[1] Univ Bologna, Sch Med, Seragnoli Inst Hematol, Bologna, Italy

[2] Mayo Clin, Dept Hematol, Rochester, MN USA

[3] Univ Turin, Div Hematol, Turin, Italy

[4] Univ Hosp, Dept Hematol, Nantes, France

[5] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA

[6] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain

[7] Univ Hamburg, Univ Med Ctr, Hamburg, Germany

[8] Wilhelminenspital Hosp, Med Dept & Med Oncol 1, Vienna, Austria

[9] Univ Athens, Sch Med, Dept Clin Therapeut, GR-11527 Athens, Greece

[10] Hop Purpan, Serv Hematol, Toulouse, France

[11] Erasmus MC, Dept Hematol, Rotterdam, Netherlands

[12] Univ Turin, Dept Med & Expt Oncol, Turin, Italy

[13] Dana Farber Canc Inst, Div Hematol Malignancy, Boston, MA 02115 USA

[14] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[15] Aarhus Univ Hosp, Med Ctr, Dept Hematol, DK-8000 Aarhus, Denmark

[16] Univ Hamburg Hosp, Dept Stem Cell Transplantat, D-2000 Hamburg, Germany

[17] Huddinge Univ Hosp, Dept Med, Stockholm, Sweden

[18] Mayo Clin Scottsdale, Dept Hematol Oncol, Scottsdale, AZ USA

[19] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[20] Wuertzburg Univ Hosp, Dept Hematol & Oncol, Wuertzburg, Germany

[21] Mt Sinai Canc Inst, New York, NY USA

[22] Cornell Univ, Ctr Lymphoma & Myeloma, Weill Med Coll, New York, NY 10021 USA

[23] Aptium Oncol, Hematol Malignancies & Multiple Myeloma, Los Angeles, CA USA

[24] Univ Salamanca, Conscjo Super Invest Cient USAL CSIC, Hosp Univ Salamanca, CIC,IBMCC, E-37008 Salamanca, Spain

[25] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA

来源：

BLOOD | 2011年 / 117卷 / 23期

关键词：

HIGH-DOSE THERAPY; BORTEZOMIB PLUS DEXAMETHASONE; BONE-MARROW-TRANSPLANTATION; PERIPHERAL NEUROPATHY; STANDARD CHEMOTHERAPY; CLINICAL-IMPLICATIONS; INDUCTION THERAPY; RANDOMIZED-TRIAL; ELDERLY-PATIENTS; YOUNGER PATIENTS;

D O I：

10.1182/blood-2011-02-297325

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The role of high-dose therapy followed by autologous stem cell transplantation (ASCT) in the treatment of multiple myeloma (MM) continues to evolve in the novel agent era. The choice of induction therapy has moved from conventional chemotherapy to newer regimens incorporating the immunomodulatory derivatives thalidomide or lenalidomide and the proteasome inhibitor bortezomib. These drugs combine well with traditional therapies and with one another to form various doublet, triplet, and quadruplet regimens. Up-front use of these induction treatments, in particular 3-drug combinations, has affected unprecedented rates of complete response that rival those previously seen with conventional chemotherapy and subsequent ASCT. Autotransplantation applied after novel-agent-based induction regimens provides further improvement in the depth of response, a gain that translates into extended progression-free survival and, potentially, overall survival. High activity shown by immunomodulatory derivatives and bortezomib before ASCT has recently led to their use as consolidation and maintenance therapies after autotransplantation. Novel agents and ASCT are complementary treatment strategies for MM. This article reviews the current literature and provides important perspectives and guidance on the major issues surrounding the optimal current management of younger, transplantation-eligible MM patients. (Blood. 2011;117(23):6063-6073)

引用

页码：6063 / 6073

页数：11

共 112 条

[111] ZAMAGNI E, 2010, BLOOD, V116
[112] Multiple Myeloma, Venous Thromboembolism, and Treatment-Related Risk of Thrombosis
Zamagni, Elena
Brioli, Annamaria
Tacchetti, Paola
Zannetti, Beatrice
Pantani, Lucia
Cavo, Michele
[J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2011, 37 (03) : 209 - 219

← 3 4 5 6 7 8 9 10 11 12 →